Skip to main content
SpringerLink
Log in

Multiple Sklerose im Kindes- und Jugendalter

Komplex, chronisch, differenziert

Multiple sclerosis in childhood and adolescence

Complex, chronic and differentiated

  • Leitthema
  • Published:
Der Nervenarzt Aims and scope Submit manuscript

Zusammenfassung

Die pädiatrische multiple Sklerose (MS) gehört zu den wichtigen erworbenen neurologischen Erkrankungen des Kindesalters, die einer frühzeitigen Erkennung, Diagnose und Behandlung bedürfen. Der Beitrag gibt eine aktuelle Übersicht über Ätiologie und Pathogenese, Diagnose, klinische Symptomatik und Therapie im Kindesalter. Trotz der in den ersten Jahren deutlich niedrigeren Behinderungsprogression im Vergleich zu Erwachsenen ist eine frühzeitige verlaufsmodifizierende Therapie indiziert.

Abstract

Pediatric multiple sclerosis (MS) is one of the most important acquired neurological disorders in childhood and adolescence. A timely recognition, diagnosis and treatment are of utmost importance. This article highlights the current state of knowledge on the etiology, pathogenesis, diagnosis, clinical presentation and treatment in childhood. Although the rate of progression of disability in the early years is slower in younger patients compared to adults, a disease-modifying therapy should be started once MS is diagnosed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Alcina A, Abad-Grau Mdel M, Fedetz M, Izquierdo G, Lucas M, Fernandez O, Ndagire D, Catala-Rabasa A, Ruiz A, Gayan J, Delgado C, Arnal C, Matesanz F (2012) Multiple sclerosis risk variant HLA-DRB1*1501 associates with high expression of DRB1 gene in different human populations. PLOS ONE 7(1):e29819. https://doi.org/10.1371/journal.pone.0029819

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Banwell B, Bar-Or A, Arnold DL, Sadovnick D, Narayanan S, McGowan M, O’Mahony J, Magalhaes S, Hanwell H, Vieth R, Tellier R, Vincent T, Disanto G, Ebers G, Wambera K, Connolly MB, Yager J, Mah JK, Booth F, Sebire G, Callen D, Meaney B, Dilenge ME, Lortie A, Pohl D, Doja A, Venketaswaran S, Levin S, Macdonald EA, Meek D, Wood E, Lowry N, Buckley D, Yim C, Awuku M, Cooper P, Grand’maison F, Baird JB, Bhan V, Marrie RA (2011) Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. Lancet Neurol 10(5):436–445. https://doi.org/10.1016/S1474-4422(11)70045-X

    Article  CAS  PubMed  Google Scholar 

  3. Baumann M, Sahin K, Lechner C, Hennes EM, Schanda K, Mader S, Karenfort M, Selch C, Hausler M, Eisenkolbl A, Salandin M, Gruber-Sedlmayr U, Blaschek A, Kraus V, Leiz S, Finsterwalder J, Gotwald T, Kuchukhidze G, Berger T, Reindl M, Rostasy K (2015) Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatr 86(3):265–272. https://doi.org/10.1136/jnnp-2014-308346

    Article  CAS  Google Scholar 

  4. Belbasis L, Bellou V, Evangelou E, Ioannidis JP, Tzoulaki I (2015) Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses. Lancet Neurol 14(3):263–273

    Article  PubMed  Google Scholar 

  5. https://www.clinicaltrials.gov. Zugegriffen: 01.08.2017

  6. Fragoso YD, Alves-Leon SV, Barreira AA, Callegaro D, Brito Ferreira ML, Finkelsztejn A, Gomes S, Magno Goncalves MV, Moraes Machado MI, Marques VD, Cunha Matta AP, Papais-Alvarenga RM, Pereira ASL, Tauil CB (2015) Fingolimod prescribed for the treatment of multiple sclerosis in patients younger than Age 18 years. Pediatr Neurol 53(2):166–168

    Article  PubMed  Google Scholar 

  7. Ghezzi A, Pozzilli C, Grimaldi LM, Brescia Morra V, Bortolon F, Capra R, Filippi M, Moiola L, Rocca MA, Rottoli M, Sarchielli P, Zaffaroni M, Comi G (2010) Safety and efficacy of natalizumab in children with multiple sclerosis. Neurology 75(10):912–917

    Article  CAS  PubMed  Google Scholar 

  8. Hennes EMBM, Schanda K et al (2017) Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Neurology 89(9):900–908

    Article  CAS  PubMed  Google Scholar 

  9. Huppke B, Ellenberger D, Rosewich H, Friede T, Gartner J, Huppke P (2014) Clinical presentation of pediatric multiple sclerosis before puberty. Eur J Neurol 21(3):441–446

    Article  CAS  PubMed  Google Scholar 

  10. Huppke P, Hummel H, Ellenberger D, Pfeifenbring S, Stark W, Huppke B, Bruck W, Gartner J (2015) JC virus antibody status in a pediatric multiple sclerosis cohort: prevalence, conversion rate and influence on disease severity. Mult Scler 21(4):382–387

    Article  CAS  PubMed  Google Scholar 

  11. Huppke P, Stark W, Zurcher C, Huppke B, Bruck W, Gartner J (2008) Natalizumab use in pediatric multiple sclerosis. Arch Neurol 65(12):1655–1658. https://doi.org/10.1001/archneur.65.12.1655

    Article  PubMed  Google Scholar 

  12. Krupp LB, Tardieu M, Amato MP, Banwell B, Chitnis T, Dale RC, Ghezzi A, Hintzen R, Kornberg A, Pohl D, Rostasy K, Tenembaum S, Wassmer E, International Pediatric Multiple Sclerosis Study G (2013) International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler 19:1261–1267

    Article  PubMed  Google Scholar 

  13. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444–1452

    Article  CAS  PubMed  Google Scholar 

  14. Mikaeloff Y, Caridade G, Tardieu M, Suissa S, KIDSEP study group (2007) Parental smoking at home and the risk of childhood-onset multiple sclerosis in children. Brain 130(10):2589–2595

    Article  PubMed  Google Scholar 

  15. Neuteboom RF, Boon M, Catsman Berrevoets CE, Vles JS, Gooskens RH, Stroink H, Vermeulen RJ, Rotteveel JJ, Ketelslegers IA, Peeters E, Poll-The BT, De Rijk-Van Andel JF, Verrips A, Hintzen RQ (2008) Prognostic factors after a first attack of inflammatory CNS demyelination in children. Neurology 71(13):967–973

    Article  CAS  PubMed  Google Scholar 

  16. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292–302

    Article  PubMed  PubMed Central  Google Scholar 

  17. Ramagopalan SV, Maugeri NJ, Handunnetthi L, Lincoln MR, Orton SM, Dyment DA, Deluca GC, Herrera BM, Chao MJ, Sadovnick AD, Ebers GC, Knight JC (2009) Expression of the multiple sclerosis-associated MHC class II allele HLA-DRB1*1501 is regulated by vitamin D. Plos Genet 5(2):e1000369

    Article  PubMed  PubMed Central  Google Scholar 

  18. Reinhardt K, Weiss S, Rosenbauer J, Gartner J, von Kries R (2014) Multiple sclerosis in children and adolescents: incidence and clinical picture – new insights from the nationwide German surveillance (2009–2011). Eur J Neurol 21(4):654–659

    Article  CAS  PubMed  Google Scholar 

  19. Renoux C, Vukusic S, Mikaeloff Y, Edan G, Clanet M, Dubois B, Debouverie M, Brochet B, Lebrun-Frenay C, Pelletier J, Moreau T, Lubetzki C, Vermersch P, Roullet E, Magy L, Tardieu M, Suissa S, Confavreux C (2007) Natural history of multiple sclerosis with childhood onset. N Engl J Med 356(25):2603–2613

    Article  CAS  PubMed  Google Scholar 

  20. Rostasy K, Bajer-Kornek B, Venkateswaran S, Hemingway C, Tardieu M (2016) Differential diagnosis and evaluation in pediatric inflammatory demyelinating disorders. Neurology 87(9 Supplement 2):S28–S37

    Article  PubMed  Google Scholar 

  21. Sadovnick AD, Yee IM, Ebers GC, Risch NJ (1998) Effect of age at onset and parental disease status on sibling risks for MS. Neurology 50(3):719–723

    Article  CAS  PubMed  Google Scholar 

  22. Stark W, Huppke P, Gartner J (2008) Paediatric multiple sclerosis: the experience of the German centre for multiple sclerosis in childhood and adolescence. J Neurol 255(S6):119–122

    Article  PubMed  Google Scholar 

  23. van Pelt ED, Mescheriakova JY, Makhani N, Ketelslegers IA, Neuteboom RF, Kundu S, Broer L, Janssens C, Catsman-Berrevoets CE, van Duijn CM, Banwell B, Bar-Or A, Hintzen RQ (2013) Risk genes associated with pediatric-onset MS but not with monophasic acquired CNS demyelination. Neurology 81(23):1996–2001

    Article  PubMed  Google Scholar 

  24. Venkateswaran S, Banwell B (2010) Pediatric multiple sclerosis. Neurologist 16(2):92–105

    Article  PubMed  Google Scholar 

  25. Waldman A, Ghezzi A, Bar-Or A, Mikaeloff Y, Tardieu M, Banwell B (2014) Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research. Lancet Neurol 13(9):936–948

    Article  PubMed  PubMed Central  Google Scholar 

  26. Waubant E, Mowry EM, Krupp L, Chitnis T, Yeh EA, Kuntz N, Ness J, Chabas D, Strober J, McDonald J, Belman A, Milazzo M, Gorman M, Weinstock-Guttman B, Rodriguez M, Oksenberg JR, James JA, US Pediatric MS Network (2011) Common viruses associated with lower pediatric multiple sclerosis risk. Neurology 76(23):1989–1995

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pädiatrische Neurologie, Zentrum für neuromuskuläre Erkrankungen und Neuroimmunologie im Kindesalter, LMU Zentrum – iSPZ Hauner, Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen Kinderspital, Universität München, München, Deutschland

    A. Blaschek & W. Müller-Felber

  2. Abteilung Pädiatrische Neurologie, Entwicklungsneurologie und Sozialpädiatrie, Dr. von Haunersches Kinderspital, Ludwig-Maximilians-Universität München, Lindwurmstraße 4, 80337, München, Deutschland

    A. Blaschek & W. Müller-Felber

  3. Abteilung Neuropädiatrie, Klinik für Kinder- und Jugendmedizin, Göttingen, Deutschland

    P. Huppke

  4. Institut für klinische Neuroimmunologie, Campus Großhadern, Klinikum der Universität München, München, Deutschland

    T. Kümpfel

  5. Biomedizinisches Centrum München, Campus Großhadern, Klinikum der Universität München, München, Deutschland

    T. Kümpfel

  6. Neuropädiatrie und Entwicklungsneurologie, Vestische Kinder- und Jugendklinik Datteln, Universität Witten/Herdecke, Witten, Deutschland

    K. Rostasy

Authors
  1. A. Blaschek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Huppke
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Kümpfel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W. Müller-Felber
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K. Rostasy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Blaschek.

Ethics declarations

Interessenkonflikt

A. Blaschek gibt an, persönliche Honorare außerhalb der hier vorgelegten Arbeit von den Firmen Novartis GmbH, Sanofi Genzyme, Santhera Pharmaceuticals Holding erhalten zu haben. P. Huppke gibt an, Reisekostenerstattung und Vortragshonorare der Firmen Bayer Healthcare, Biogen idec, Novartis und Merck/Serono erhalten zu haben. T. Kümpfel hat Reisekostenerstattung und Vortragshonorare der Firmen Bayer Healthcare, Teva Pharma, Merck, Novartis Pharma, Sanofi-Aventis/Genzyme, CLS Behring, Roche Pharma und Biogen sowie Fördermittel der Firmen Bayer-Schering AG, Novartis und Chugai Pharma erhalten. W. Müller-Felber ist Mitglied im Advisory Board der Firmen Biogen, Avexis. K. Rostasy gibt persönliche Honorare der Fa. Novartis GmbH an.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Blaschek, A., Huppke, P., Kümpfel, T. et al. Multiple Sklerose im Kindes- und Jugendalter. Nervenarzt 88, 1377–1384 (2017). https://doi.org/10.1007/s00115-017-0422-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00115-017-0422-z

Schlüsselwörter

Keywords

Search

Navigation